TLIS: Talis Biomedical Corp. Price to Sales

Symbol and logo of brand Talis Biomedical Corp (TLIS)

Talis Biomedical is developing cloud services for the molecular analysis of infections in clinical and home settings. The divergence of the P/S ratio from its historical average serves as a confidence indicator, where 26.60 becomes the new value for this metric. The business model of selling readers and high-margin cartridges ensures scalability, although delays in bringing platforms to market have created redundant costs, temporarily suppressing operating leverage.

TLIS (Talis Biomedical Corp) P/S Multiple history from 07/04/2022 to 09/07/2024

Analytical breakdowns for Talis Biomedical (TLIS)

- market price and analyst price targets:
Stock Quotes talis.bio|TLIS - Analyst Consensus Forecast
- market capitalization information:
Market Value Talis Biomedical Corp|TLIS - Enterprise Value
- shareholders' equity book value data:
Equity per Share Talis Biomedical|TLIS - Book Capitalization|Market Capitalization to Book Value talis.bio|TLIS - Company Total Assets
- debt obligations and liquidity statistics:
Total Debt to Equity Ratio Talis Biomedical|TLIS - Long-Term Debt to Capital|Short-Term Debt to Capital talis.bio|TLIS - Company Debts|Debt to Book Capitalization Ratio Talis Biomedical Corp|TLIS - Company Long-Term Liabilities|Company Short-Term Loans and Borrowings Talis Biomedical|Immediate Liquidity talis.bio
- net income and valuation multiples indicators:
TLIS - Company Net Income|Projected Net Profit Talis Biomedical|TLIS - Price to Earnings Ratio|Forward P/E Multiple talis.bio|TLIS - PEG Multiple|Total Company Value to Operating Income Before Depreciation Ratio Talis Biomedical Corp|TLIS - Profit before payment of interest, taxes and amortization|Earnings per one share for the last 12 months Talis Biomedical|TLIS - Earnings per share for the last twelve months|Year-over-year net earnings per share growth for the last 12 months talis.bio|TLIS - Earnings growth in current year|Expected net earnings per share growth next year Talis Biomedical
- issuer revenue and sales details:
TLIS - Company Revenue|Company Revenue Forecast talis.bio|TLIS - Market Cap to Revenue|Price to Expected Revenue Ratio Talis Biomedical Corp
Fundamental company analysis:Talis Biomedical Corp. TLIS
Original product of Talis Biomedical

Talis Biomedical is implementing AI-driven molecular diagnostic systems to automate rapid testing, positioning revenue as the primary driver of business value. The price-to-sales ratio measures the market premium paid per unit of revenue, allowing investors to utilize a P/S multiplier chart to determine the asset's degree of undervaluation and avoid locking up capital in an overbought instrument.

Who Talis Biomedical competes with

Market Cap to Revenue abbott.com ABT|P/S Multiple TMO (Thermo Fisher)|GE HealthCare Technologies Inc. (GEHC) - Price to Sales|Mettler-Toledo International Inc. - P/S Multiple|WAT (Waters Technologies) - Market Cap to Revenue Ratio|TECH: P/S Multiple|BRKR - Price-to-Revenue Coefficient|AZTA (Azenta) - P/S Multiple|Market Cap to Revenue Varex Imaging Corp (VREX)|P/S Multiple SMLR|P/S Multiple Butterfly Corp (BFLY)|Price-to-Revenue Ratio Mesa Laboratories, Inc. MLAB|quantum-si.com - Price-to-Revenue Ratio|NNOX: Market Cap to Revenue|Market Capitalization-to-Revenue Ratio QTRX (Quanterix Corp.)|MASS: P/S Multiple|Price to Sales CapsoVision (CV)|Price-to-Revenue Ratio MaxCyte, Inc.|RPID - Price-to-Revenue Multiple|Market Cap to Revenue SEER (Seer)|P/S Multiple Hyperfine Inc (HYPR)|P/S Multiple FONR (FONAR Corp)|Price-to-Revenue Coefficient Daxor Corp (DXR)|MDAI - Price-to-Revenue Ratio|Price-to-Sales Ratio VIVS|Aclarion, Inc. (ACON) - Price-to-Revenue Ratio|Market Cap to Revenue Akoya Biosciences, Inc.|THMO (ThermoGenesis Holdings Inc.) - P/S Multiple|Price to Sales T2 Biosystems Inc TTOO